Predicting colorectal adenomatous polyps in patients with chronic liver disease: A novel nomogram

Figure 3 Nomogram and performance metrics for predicting the risk of adenomatous polyps. A: Nomogram; B: In the training group, the area under curve (AUC) was 0.801 (95% confidence interval: 0.756-0.854). The impact on AUC from age, gender, body mass index, alcohol consumption, serum ferritin, and overlapping metabolic dysfunction-associated steatotic liver disease was 0.64, 0.65, 0.61, 0.62, 0.62, and 0.60, respectively; C: In the validation group, the AUC was 0.785 (95% confidence interval: 0.712-0.858); D: Internal validation among chronic liver disease patients yielded the following AUCs: Hepatitis B virus: 0.769, hepatitis C virus: 0.800, alcoholic liver disease: 0.892, drug-induced liver injury: 0.812, primary biliary cholangitis: 0.970, autoimmune hepatitis: 0.900. BMI: Body mass index; OLDs-MASLD: Other liver diseases overlapping metabolic dysfunction associated steatotic liver disease; SF: Serum ferritin; AUC: Area under curve; CI: Confidence interval; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALD: Alcoholic liver disease; DILI: Drug-induced liver injury; PBC: Primary biliary cholangitis; AIH: Autoimmune hepatitis.